CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
375.54MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6120xvs all stocks
52-Week Change
-58.02%vs all stocks
Market Capitalization
375.54MUSDvs all stocks (USD)
Enterprise Value
270.35MUSDvs all stocks (USD)
Forward P/E
-6.23xvs Biotechnology peers
Price to Book (MRQ)
3.74xvs Biotechnology peers
Enterprise to EBITDA
-3.32xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-35.32%vs Biotechnology peers
Return on Equity (TTM)
-59.04%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-81.44MUSDvs all stocks (USD)
Net Income (TTM)
-77.59MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-64.64MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-36.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Jun 30, 2025Operating Income
-79.89MUSDvs all stocks (USD)
Pre-tax Income
-74.41MUSDFY2025 · Jun 30, 2025Net Income
-74.41MUSDFY2025 · Jun 30, 2025EBIT
-79.89MUSDFY2025 · Jun 30, 2025EBITDA (Income Statement)
-79.86MUSDFY2025 · Jun 30, 2025Research & Development
61.53MUSDFY2025 · Jun 30, 2025Selling, General & Administrative
18.37MUSDFY2025 · Jun 30, 2025Non-operating Interest Income
5.48MUSDFY2025 · Jun 30, 2025EPS (Basic)
-0.9800USDFY2025 · Jun 30, 2025EPS (Diluted)
-0.9800USDFY2025 · Jun 30, 2025Basic Shares Outstanding
76.00MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
76.00MSharesFY2025 · Jun 30, 2025Net Income from Continuing Operations
-74.41MUSDFY2025 · Jun 30, 2025Operating Cash Flow
-65.31MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
94.11MUSDFY2025 · Jun 30, 2025Income Tax Paid
0.00USDFY2025 · Jun 30, 2025Interest Paid
0.00USDFY2025 · Jun 30, 2025Starting Profit (CF Statement)
-74.41MUSDFY2025 · Jun 30, 2025Depreciation & Amortization
31.00KUSDFY2025 · Jun 30, 2025Stock-based Compensation
7.12MUSDFY2025 · Jun 30, 2025Other Non-cash Items
532.00KUSDFY2025 · Jun 30, 2025Change in Accounts Payable (CF)
1.42MUSDFY2025 · Jun 30, 2025Purchase of Investments
-128.14MUSDFY2025 · Jun 30, 2025Sale of Investments
113.60MUSDFY2025 · Jun 30, 2025Net Investing Cash Flow
-14.54MUSDFY2025 · Jun 30, 2025Other Financing Charges
-1.06MUSDFY2025 · Jun 30, 2025Net Financing Cash Flow
85.34MUSDFY2025 · Jun 30, 2025Shares Outstanding
96.29MSharesUpdated Sep 28, 2026Float Shares
60.90MSharesUpdated Sep 28, 2026Shares Short
16.81MSharesUpdated Sep 28, 2026Short Ratio
12.31daysvs all stocks
Short % of Shares Outstanding
26.29%vs all stocks
% Held by Insiders
10.10%vs all stocks
% Held by Institutions
98.36%vs all stocks
Total Cash (MRQ)
107.80MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.11USDUpdated Sep 28, 2026Total Debt (MRQ)
934.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0093xvs Biotechnology peers
Current Ratio (MRQ)
9.68xvs Biotechnology peers
Book Value per Share (MRQ)
1.04USDUpdated Sep 28, 2026Total Assets
175.49MUSDvs all stocks (USD)
Total Current Assets
171.15MUSDFY2025 · Jun 30, 2025Total Liabilities
13.36MUSDFY2025 · Jun 30, 2025Total Non-current Assets
4.34MUSDFY2025 · Jun 30, 2025Total Non-current Liabilities
1.45MUSDFY2025 · Jun 30, 2025Total Current Liabilities
11.91MUSDFY2025 · Jun 30, 2025Cash
5.05MUSDFY2025 · Jun 30, 2025Cash Equivalents
89.06MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents
94.11MUSDFY2025 · Jun 30, 2025Other Short-term Investments
73.75MUSDFY2025 · Jun 30, 2025Accounts Payable
5.81MUSDFY2025 · Jun 30, 2025Short-term Debt
632.00KUSDFY2025 · Jun 30, 2025Long-term Debt
983.00KUSDFY2025 · Jun 30, 2025Common Stock (Book)
87.00KUSDFY2025 · Jun 30, 2025Retained Earnings
-403.86MUSDFY2025 · Jun 30, 2025Total Shareholders' Equity
162.13MUSDvs all stocks (USD)
52-Week Low
1.07USDUpdated Sep 28, 202652-Week High
11.46USDUpdated Sep 28, 202652-Week Change
-58.02%vs all stocks
Beta
0.6120xvs all stocks
50-Day MA
4.58USDUpdated Sep 28, 2026200-Day MA
3.73USDUpdated Sep 28, 2026Avg 10-Day Volume
1.76MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.51MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.8000USDUpdated Sep 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.70
Altman Z-Score 13.23: safe zoneNotable
Altman Z-Score: 13.23
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule